Achondroplasia: genetic disorder causing short-limbed short stature

Cause and genetics

The condition results from a variant in the fibroblast growth factor receptor 3 gene (FGFR3). FGFR3 normally helps regulate bone growth by slowing the maturation of cartilage into bone during development. The variant increases FGFR3 activity and restricts endochondral bone growth, producing the characteristic limb shortening. Achondroplasia follows an autosomal dominant inheritance pattern: a person who carries one altered copy of the gene usually shows the trait and has about a 50% chance of passing it to each child. Many cases, however, arise from a spontaneous (de novo) mutation in a child of parents of average stature.

Typical features and complications

Characteristic physical findings include rhizomelic shortening (shortening of the upper arms and thighs), an enlarged head with prominent forehead (frontal bossing), midface underdevelopment, and a specific hand shape often described as "trident". Intelligence is usually normal. Potential medical issues can include spinal stenosis, foramen magnum narrowing in infants, recurrent ear infections with hearing loss, sleep-disordered breathing, and a tendency toward obesity. Orthopedic and neurosurgical complications sometimes require specialist care.

Diagnosis and evaluation

Diagnosis is typically based on clinical examination and skeletal radiographs that show characteristic bone proportions and changes. Molecular genetic testing of FGFR3 can confirm the diagnosis and distinguish achondroplasia from other forms of skeletal dysplasia. Early assessment often includes evaluation for foramen magnum compression, hearing, growth monitoring, and developmental surveillance.

Management and prognosis

There is no cure, but multidisciplinary care improves outcomes. Management focuses on monitoring growth and development, treating complications (for example, surgical decompression for severe foramen magnum stenosis or interventions for obstructive sleep apnea), and addressing hearing and recurrent ear infections. Physical therapy, occupational therapy, and social support aid mobility and independence. In recent years, targeted medical approaches that modify FGFR3 signaling have been investigated, and some therapies have shown promise in increasing growth velocity in children with achondroplasia.

History, prevalence, and distinctions

The word achondroplasia comes from Greek roots meaning "without cartilage formation," though the biology involves altered cartilage-to-bone conversion rather than absence of cartilage. The molecular cause was identified in the late 20th century, improving diagnostic certainty and opening avenues for targeted treatment research. Achondroplasia should be distinguished from other skeletal dysplasias by its typical proportions, radiographic pattern and FGFR3 testing. It occurs worldwide and is relatively uncommon—seen in roughly one in many thousands of births.

Further information

• Skeletal dysplasia and bone growth
• Femur and long bone involvement
• Upper limb (humerus) characteristics
• Genetic testing and FGFR3
• Cartilage, endochondral ossification, and development

For people, families and clinicians, management aims to preserve health, function and quality of life through informed surveillance, timely treatment of complications, and community support.